IP Library Granted Patent US 8,614,224
Granted Patent B2
US 8,614,224 · App. 13/352,668 · Granted Dec 24, 2013

Sinomenine derivatives and processes for their synthesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,614,224
App. No.
13/352,668
Granted
Dec 24, 2013
Kind
B2
Abstract

The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.

Claims (115)

1. A compound having Formula (I):

wherein:

R 1 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 is halogen;

R 3 is selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 4 is OR 4a ;

R 4a is a bond that forms park of an ether-containing ring;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 7 is OR 7a ;

R 7a is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 8 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 9 and R 10 together may form a group selected from the group consisting of ═O and ═S;

R 11 and R 12 are independently selected from the group consisting of hydrogen, OH, halogen, hydrocarbyl, and substituted hydrocarbyl;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl;

m is an integer from 0 to 8; and

----- is a single bond or a double bond,

and further wherein C9, C13 and C14 reference carbon numbers 9, 13 and 14, respectively, of Formula (I).

2. The compound of claim 1 , wherein:

R 1 is selected from the group consisting of an alkyl group having from 1 to 8 carbon atoms, a vinyl group, an aryl group, cyclopropyl, cyclobutyl, {—}CH(CF 3 ) 2 , {—}CH(CH 3 )CF 3 , {—}CH═CF 2 , and {—}CH 2 CF 3 ;

R 2 is halogen;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, and NH 2 , wherein R 5 and R 6 together may form ═O;

R 3 and R 8 -R 12 are each hydrogen;

Y is selected from the group consisting of {—}CH 2 {—} and {—}CO{—}; and

m is 0.

3. The compound of claim 1 , wherein the compound has Formula (Ia):

wherein:

R 2 is halogen;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 7 is OR 7a ;

R 7a is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 8 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 9 and R 10 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 9 and R 10 together may form a group selected from the group consisting of ═O and ═S;

Z is {—}O{—}; and

----- is a single bond or a double bond.

4. The compound of claim 1 , wherein the compound has Formula (Ib):

wherein:

R 2 is halogen;

R 4 is OR 4a ;

R 4a is a bond that forms part of an ether-containing ring;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 7 is OR 7a ;

R 7a is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl; and

----- is a single bond or a double bond.

5. The compound of claim 1 , wherein the compound is selected from the group consisting of:

wherein X is halogen.

6. The compound of claim 1 , wherein the optical activity of the compound is (−) or (+) and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRS, RSS, SRR, and SSR.

7. A process for preparing a compound of Formula (I) of claim 1 , the process comprising contacting a compound having Formula 5a with a proton acceptor to form a compound of Formula (I) according to the reaction scheme:

wherein

R 1 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 is halogen;

R 3 is selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 4 is OH;

R 9 and R 10 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 9 and R 10 together may form a group selected from the group consisting of ═O and ═S; and

X is halogen;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl;

m is an integer from 0 to 8; and

Z is {—}O{—},

and further wherein C5, C9, C13 and C14 reference carbon numbers 5, 9, 13 and 14, respectively, of the compound of Formula (I).

8. The process of claim 7 , wherein the reaction is conducted in the presence of an aprotic solvent; the weight ratio of solvent to compound 5a is from about 5:1 to about 50:1; the proton acceptor has a pKa greater than about 13; the weight ratio of compound 5a to proton acceptor is from about 1:1.5 to about 1:20; the reaction is conducted at a temperature ranging from about −30° C. to about 0° C.; and the optical activity of compounds 5a and (I) is (−) or (+), and the configuration of C5, C13, C14, and C9, respectively, is selected from the group consisting of RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR.

9. A compound having Formula (Ic):

wherein:

R 2 is halogen;

R 4 is OR 4a ;

R 4a is a bond that forms part of an ether-containing ring;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—; and

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl.

10. A process for preparing a compound of Formula (Ic) of claim 9 , the process comprising contacting a compound having Formula 6a with a scavenger and a proton donor to form the compound of Formula (Ic) according to the reaction scheme:

wherein

R 1 is selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 2 is halogen;

R 7 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 8 and R 9 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 8 and R 9 together may form a group selected from the group consisting of ═O and ═S;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl;

m is an integer from 0 to 8; and

Z is {—}O{—},

and further wherein C5, C9, C13 and C14 reference carbon numbers 5, 9, 13 and 14, respectively, of the compounds of Formulas 6 and (Ic).

11. The process of claim 10 , wherein the reaction is conducted in the presence of an aprotic solvent; the weight ratio of solvent to compound 6a is from about 5:1 to about 50:1; the scavenger is an alcohol scavenger; the proton donor has a pKa less than about 0; the weight ratio of compound 6a to scavenger to proton donor is from about 1:0.5:2 to about 1:2:20; the reaction is conducted at a temperature ranging from about 0° C. to about 100° C.; and the optical activity of compounds 6a and (Ic) is (−) or (+), and the configuration of C5, C13, C14, and C9, respectively, is selected from the group consisting of RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR.

12. A process for preparation of a compound of Formula (Ic) of claim 9 according to the following reaction scheme:

wherein:

R 1 is selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 4 is selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, ═S, ═CHR 5a , and —O(CH 2 ) 2 O—;

R 5a is selected from the group consisting of hydrogen, halogen, hydrocarbyl, and substituted hydrocarbyl;

R 7 and R 8 are independently selected from the group consisting of hydrogen, OH, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 7 and R 8 together may form a group selected from the group consisting of ═O and ═S;

X is halogen;

Y is selected from the group consisting of alkyl, substituted alkyl, carbonyl, and alkyl carbonyl; and

Z is {—}O{—},

and further wherein C9, C13 and C14 reference carbon numbers 9, 13 and 14, respectively, of Formulas 2, 3, 4, 5, 6, and (Ic), and C5 references carbon number 5 of Formulas 6 and (Ic).

13. The process of claim 12 , wherein:

R 1 is selected from the group consisting of an alkyl group having from 1 to 8 carbon atoms, a vinyl group, an aryl group, cyclopropyl, cyclobutyl, {—}CH(CF 3 ) 2 , {—}CH(CH 3 )CF 3 , {—}CH═CF 2 , and {—}CH 2 CF 3 ;

R 2 and R 3 are independently selected from the group consisting of hydrogen, halogen, OH, NH 2 , CN, acyl, an alkyl, alkenyl, aryl, alkoxyl, and alkylamino;

R 4 is selected from the group consisting of hydrogen and alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, OH, and alkoxyl, wherein R 5 and R 6 together may form a group selected from the group consisting of ═O, ═NOH, and —O(CH 2 ) 2 O—;

R 7 and R 8 are independently selected from the group consisting of hydrogen, OH and NH 2 , wherein R 7 and R 8 together may form ═O;

X is selected from the group consisting of bromide and chloride;

Y is selected from the group consisting of {—}CH 2 {—} and {—}CO{—}; and

Z is {—}O{—}.

14. The process of claim 13 , wherein:

R 1 is cyclopropyl;

R 2 is hydrogen;

R 3 is {—}O(CH 2 ) m CH 3 ;

R 5 and R 6 together form ═O;

R 4 , R 7 , and R 8 are each hydrogen; and

m is an integer from 0 to 8.

15. The process of claim 12 , wherein the weight ratio of compound 2 to vinyl chloroformate or 1-chloroethyl chloroformate to proton acceptor or proton donor is from about 1:2:1 to about 1:20:20, the reaction of Step A is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 50° C. to about 120° C.; the weight ratio of compound 3 to R 1 YX or R 1 Y is from about 1:1 to about 1:3, the reaction of Step B is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 20° C. to about 100° C.; the weight ratio of compound 4 to X 2 is from about 1:2 to about 1:2.5, the reaction of Step C is conducted in the presence of an organic solvent, and at a temperature ranging from about −30° C. to about 0° C.; the weight ratio of compound 5 to proton acceptor is from about 1:1.5 to about 1:20, the reaction of Step D is conducted in the presence of an aprotic and/or a protic solvent, and at a temperature ranging from about −30° C. to about 0° C.; and the weight ratio of compound 6 to scavenger to proton donor is from about 1:0.5:2 to about 1:2:20, the reaction of Step E is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 0° C. to about 100° C.

16. The process of claim 15 , wherein the proton acceptor has a pKa greater than about 13 and is selected from the group consisting of NaOH, KOH, LiOH, Ca(OH) 2 , and NaH; the scavenger is an alcohol scavenger selected from the group consisting of P 2 O 5 , POCl 3 , POBr 3 , PCl 3 , PBr 3 , SOCl 2 , SOBr 2 , MeSO 2 Cl, (MeSO 2 ) 2 O, SO 3 , (CF 3 SO 2 ) 2 O, and (CF 3 CO) 2 O; and the proton acceptor has a pKa less than about 0 and is selected from the group consisting of MeSO 3 H, poly H 3 PO 4 , H 3 PO 4 , H 2 SO 4 , HCl, HBr, HlO 4 , HNO 3 , CF 3 SO 3 H, and p-methyltoluenesulfonic acid.

17. The process of claim 12 , wherein the optical activity of compounds 2, 3, 4 and 5 is (−) or (+), and the configuration of C13, C14, and C9, respectively, is selected from the group consisting of RRS, RSS, SRR, and SSR.

18. The process of claim 12 , wherein the optical activity of compounds 6 and (Ic) is (−) or (+), and the configuration of C5, C13, C14, and C9, respectively, is selected from the group consisting of RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR.

19. The compound of claim 9 , wherein R 5 and R 6 together form ═O.

20. The compound of claim 9 , wherein R 5 is OH.

21. The compound of claim 9 , wherein R 5 is NH 2 .

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →